.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Fuji
McKinsey
Fish and Richardson
Merck
Daiichi Sankyo
Federal Trade Commission
Julphar
Accenture
Cerilliant

Generated: November 25, 2017

DrugPatentWatch Database Preview

PAXIL Drug Profile

« Back to Dashboard

What is the patent landscape for Paxil, and what generic Paxil alternatives are available?

Paxil is a drug marketed by Apotex Technologies and is included in four NDAs. There are five patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and sixty-six patent family members in thirty-nine countries.

The generic ingredient in PAXIL is paroxetine hydrochloride. There are thirty drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the paroxetine hydrochloride profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Technologies
PAXIL
paroxetine hydrochloride
SUSPENSION;ORAL020710-001Jun 25, 1997RXYesYes► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-004Oct 9, 1998DISCNYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL CR
paroxetine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020936-002Feb 16, 1999ABRXYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-001Oct 9, 1998DISCNYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
TABLET;ORAL020031-003Dec 29, 1992ABRXYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-002Oct 9, 1998DISCNYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL CR
paroxetine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020936-001Feb 16, 1999ABRXYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-001Oct 9, 1998DISCNYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL CR
paroxetine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020936-001Feb 16, 1999ABRXYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL CR
paroxetine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020936-003Dec 6, 2000ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for PAXIL

Drugname Dosage Strength RLD Submissiondate
paroxetine hydrochlorideExtended-release Tablets37.5 mgPaxil CR5/19/2009
paroxetine hydrochlorideExtended-release Tablets25 mgPaxil CR9/9/2005
paroxetine hydrochlorideOral Suspension10 mg/5 mLPaxil2/10/2005

International Patent Family for Tradename: PAXIL

Country Document Number Estimated Expiration
Hungary0103712► Subscribe
Slovenia1089996► Subscribe
United Kingdom9605828► Subscribe
Norway991944► Subscribe
Turkey200100055► Subscribe
ItalyMI990866► Subscribe
Ireland20000633► Subscribe
Australia1573100► Subscribe
France2780728► Subscribe
Austria3185► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Cantor Fitzgerald
AstraZeneca
US Department of Justice
Johnson and Johnson
Express Scripts
Covington
Medtronic
Novartis
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot